This cluster groups 2 independently calculated changes: Cash & equivalents decreased 31.2%; Operating cash flow decreased 78.8%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTGrace Therapeutics, Inc.'s latest supported as-filed period reports revenue of $100.0M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 31.2%; Operating cash flow decreased 78.8%.
2 evidence-backed componentsShares outstanding changed +52.1% from the comparable as-filed period. The change ranks at the 71th percentile of 7 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
GRCE · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001493152-26-042152SEC ↗4Sep 10, 2026Period Sep 9, 20260001140361-26-036125SEC ↗4Sep 1, 2026Period Aug 28, 20260001140361-26-035318SEC ↗4Sep 1, 2026Period Aug 28, 20260001140361-26-035317SEC ↗4Sep 1, 2026Period Aug 28, 20260001140361-26-035319SEC ↗4Sep 1, 2026Period Aug 28, 20260001140361-26-035316SEC ↗4Aug 19, 2026Period Aug 14, 20260001493152-26-039124SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 9, 2026Filed Sep 10, 2026 | Kohli PrashantChief Executive Officer | Open Market PurchaseDirect | 100,000 | $2 | $214,000 | Form 4 ↗ |
| Sep 9, 2026Filed Sep 10, 2026 | Opaleye Management Inc.Reporting owner | Open Market PurchaseIndirect | 5,836 | $2 | $12,197 | Form 4 ↗ |
| Sep 8, 2026Filed Sep 10, 2026 | Opaleye Management Inc.Reporting owner | Open Market PurchaseIndirect | 9,393 | $2 | $19,699 | Form 4 ↗ |
| Aug 28, 2026Filed Sep 1, 2026 | Kohli PrashantChief Executive Officer | Grant Or AwardDirect | 267,160 | $0 | $0 | Form 4 ↗ |
| Aug 14, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -415.1% from the comparable as-filed period.
Operating cash flow changed -78.8% from the comparable as-filed period.
Current liabilities changed -46.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -31.2% from the comparable as-filed period.
Current ratio changed +29.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Current assets changed -30.2% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001140361-26-032644| Opaleye Management Inc.Reporting owner |
| Open Market PurchaseIndirect |
| 11,608 |
| $2 |
| $24,206 |
| Form 4 ↗ |